Cohort study shows SGLT2 inhibitors reduce kidney and cardiovascular risks in those with liver cirrhosis, suggesting important benefits.
In this cohort study of patients with T2D and liver cirrhosis, the use of SGLT2is was associated with substantially lower risks of adverse kidney, cardiovascular, and hepatic outcomes compared with DPP4is. These findings suggested significant cardiorenal and hepatic protection for SGLT2is in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: